Welcome to our dedicated page for Sensei Biotherapeutics SEC filings (Ticker: SNSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sensei Biotherapeutics, Inc. filings document a Nasdaq-listed clinical-stage oncology company, its common stock, and its disclosure obligations around pipeline development, operating results, governance, and capital structure. Material-event reports cover financial results, Regulation FD disclosures, board composition and compensation arrangements, and the completed acquisition of Faeth Therapeutics, including acquired-business financial statements and pro forma combined financial information.
Proxy and governance filings describe shareholder voting matters, director and board matters, equity compensation, preferred stock conversion-related disclosures, authorized-share matters, material agreements, and other capital-structure topics. The filing record also reflects clinical and regulatory disclosure categories for PIKTOR and solnerstotug within the company’s oncology development business.
What happened: Sensei Biotherapeutics issued a press release announcing its financial results for the quarter ended June 30, 2025.
Why it matters: The press release is attached to this Form 8-K as Exhibit 99.1, so investors can read the company’s reported results and commentary. The filing explicitly states the exhibit is being furnished, not filed, and therefore is not treated the same as a formally filed disclosure or incorporated by reference.
What to do: Review Exhibit 99.1 for the actual figures and management comments, since this 8-K itself does not include the financial numbers.